Belviq works by activating the serotonin 2C receptor in the brain. Activation of this receptor may help a person eat less and feel full after eating smaller amounts of food. The safety and efficacy of Belviq were evaluated in three randomized, placebo-controlled trials that included nearly 8,000 obese and overweight patients, with and without type 2 diabetes, treated for 52 to 104 weeks. The drug’s manufacturer will be required to conduct six postmarketing studies, including a long-term cardiovascular outcomes trial to assess the effect of Belviq on the risk for major adverse cardiac events such as heart attack and stroke.
The FDA is continuing to evaluate the phentermine/topiramate combination known as Qnexa for approval as a weight loss drug. Read more about it in the Med Check column of Psychiatric News here.
(Image: wavebreakmedia ltd/Shutterstock.com)